Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

33.81 -0.91 (-2.62%)

Streaming Delayed Price Updated: 12:22 PM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update

February 13, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences's Earnings Outlook ↗

February 10, 2023

Via Benzinga

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

February 02, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences Announces Proposed Public Offering of Common Shares

February 01, 2023

From Roivant Sciences

Via GlobeNewswire

Where Roivant Sciences Stands With Analysts ↗

January 19, 2023

Via Benzinga

Analyst Ratings for Roivant Sciences ↗

June 29, 2022

Within the last quarter, Roivant Sciences (NASDAQ:ROIV) has observed the following analyst ratings:

Via Benzinga

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023

January 30, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate ↗

January 04, 2023

Via Benzinga

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker

January 04, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases ↗

June 28, 2022

Via Benzinga

Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday ↗

December 19, 2022

Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on...

Via Benzinga

Why Roivant Sciences' Shares Are Up Thursday ↗

December 01, 2022

The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis.

Via The Motley Fool

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

December 01, 2022

From Roivant Sciences

Via GlobeNewswire

Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90% ↗

November 15, 2022

Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in...

Via Benzinga

Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94% ↗

November 15, 2022

Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.

Via Benzinga

Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

November 14, 2022

From Roivant Sciences

Via GlobeNewswire

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

November 10, 2022

From Roivant Sciences

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 08, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.

Via Benzinga

Earnings Scheduled For November 14, 2022 ↗

November 14, 2022

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

Via Benzinga

Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering

November 08, 2022

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences Announces Proposed Public Equity Offering

November 07, 2022

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences

October 18, 2022

From Roivant Sciences

Via GlobeNewswire

Tilray Brands, Canopy Growth, Cronos Group And Other Big Gainers From Thursday ↗

October 07, 2022

U.S. stocks closed lower with the Dow Jones dropping more than 300 points on Thursday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday ↗

October 06, 2022

Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.

Via Benzinga

Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say ↗

September 29, 2022

Via Benzinga

Expert Ratings for Roivant Sciences ↗

August 16, 2022

Over the past 3 months, 4 analysts have published their opinion on Roivant Sciences (NASDAQ:ROIV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...

Via Benzinga

JELD-WEN, Royal Caribbean Cruises And Some Other Big Stocks Moving Lower On Monday ↗

August 01, 2022

FiscalNote Holdings Inc. (NYSE: NOTE) fell 22.7% to $6.43. FiscalNote closed its earlier-announced agreement to acquire Aicel Technologies.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 18, 2022

Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million.

Via Benzinga

The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives ↗

June 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For August 15, 2022 ↗

August 15, 2022

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.